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Summary
Distinct phenotypes of chronic lung allograft dysfunction (CLAD) after lung
transplantation are emerging with lymphocytic bronchiolitis (LB)/azithromycin
reversible allograft dysfunction (ARAD), classical or fibrotic bronchiolitis obliter-
ans syndrome (BOS), and restrictive allograft syndrome (RAS) proposed as sepa-
rate entities. We have additionally identified lung transplant recipients with prior
LB, demonstrating persistent airway neutrophilia (PAN) despite azithromycin
treatment. The aim of this study was to evaluate differences in the airway micro-
environment in different phenotypes of CLAD. Bronchoalveolar lavage (BAL)
from recipients identified as stable (control), LB/ARAD, PAN, BOS, and RAS
were evaluated for differential cell counts and concentrations of IL-1a, IL-1b, IL-
6, IL-8, and TNF-a. Primary human bronchial epithelial cells were exposed to
BAL supernatants from different phenotypes and their viability measured. BOS
and RAS showed increased BAL neutrophilia but no change in cytokine concen-
trations compared with prediagnosis. In both LB/ARAD and PAN, significant
increases in IL-1a, IL-1b, and IL-8 were present. BAL IL-6 and TNF-a concentra-
tions were increased in PAN and only this phenotype demonstrated decreased
epithelial cell viability after exposure to BAL fluid. This study demonstrates clear
differences in the airway microenvironment between different CLAD phenotypes.
Systematic phenotyping of CLAD may help the development of more personal-
ized approaches to treatment.
Introduction
Lung transplantation (LTx) is accepted as a well-established
therapeutic option for patients with end-stage lung disease,
yet long-term survival remains less than that achieved in
transplantation of other solid organs, with a median sur-
vival of 5 years [1]. Predominantly, this is limited by the
development of chronic rejection, which affects 45–50% of
LTx patients within 5 years and accounts for more than
30% of late mortality [2]. Chronic rejection was defined as
an abnormal, airway-centered, inflammatory response
resulting in fibroproliferative small airway obliteration. The
cellular mechanisms driving chronic rejection remain
poorly elucidated, but current consensus suggests that both
alloantigen-dependent [3,4] and alloantigen-independent
insults to airway epithelium lead to an influx of inflamma-
tory cells, chronic neutrophilic inflammation, deregulated
repair, and resultant fibrotic plugging of the small airways
presenting in the typical obliterative bronchiolitis (OB)
lesions [5,6]. A multitude of risk factors have been identi-
fied, which include HLA mismatch [7], acute rejection epi-
sodes [8], recipient age [9], CMV [10], community
respiratory viral infections [11], pseudomonal colonization
[12], lymphocytic bronchitis/bronchiolitis [13],
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gastroesophageal reflux [14], air pollution [15], and ische-
mia–reperfusion injury [16]. Additionally, recent observa-
tions suggest that proinflammatory cytokines such as IL-1
family members, TNF-a [17], and IL-17 [18,19] may be the
key mediators driving these insults, via subsequent induc-
tion of the potent neutrophilic chemoattractant protein IL-
8. One of the characteristics of chronic rejection is damage
to the bronchial epithelium [20]. Previous studies have
demonstrated that damage to epithelium may result in the
release of alarmins, including IL-1a, which in a paracrine
manner may trigger expression of proinflammatory cyto-
kines in lung fibroblasts and other epithelial cells [21].
Clinically, chronic rejection manifests with persistent
cough, increased sputum production, dyspnea, and coarse
crackles and can be quantified functionally by a progressive
loss of forced expiratory volume in one second (FEV1).
Traditionally, this clinical presentation would have been
labeled as bronchiolitis obliterans syndrome (BOS) but
more recently has been termed chronic lung allograft dys-
function (CLAD) [22,23]. CLAD is used to reflect the het-
erogeneous nature of the pathophysiology characterized by
different levels of airway neutrophilia, airway and paren-
chymal fibrosis, distinct histological features, and differing
responsiveness to macrolide antibiotics [23]. On the basis
of these criteria, it has recently been proposed that CLAD
can be differentiated into two subphenotypes: classical BOS
and restrictive allograft syndrome (RAS) [24]. Azithromy-
cin reversible airways dysfunction (ARAD), a clinical con-
dition characterized by an obstructive decline in
pulmonary function, increased BAL neutrophils and
improvement in both these findings with azithromycin
treatment, is currently considered as a separate entity,
which due to its reversible nature cannot be classified as
CLAD anymore [24]. The only very recently identified
CLAD phenotype, RAS, is characterized by parenchymal
infiltrates on HRCT scan histological appearance of paren-
chymal fibrosis usually in combination with the typical OB
lesions; and a restrictive pulmonary function defect [25].
Classical BOS, on the other hand shows no neutrophilic
airway inflammation, is not reversible by azithromycin and
has radiological evidence of air trapping due to OB causing
airway obliteration [26]. ARAD associated with a neutro-
philic airway inflammation that can be attenuated by azi-
thromycin therapy is mechanistically identical to
lymphocytic bronchiolitis (LB) (also called B grade acute
rejection) given that both are IL-17-mediated conditions.
Currently, in both the Leuven and Newcastle lung trans-
plant centers, we are observing lung transplant patients,
who develop persistent, neutrophilic airway inflammation
despite azithromycin therapy for more than 3-week dura-
tion (denominated PAN or persistent airway neutrophilia
in the current paper) in the absence of submucosal demon-
strable IL-17 T lymphocytes [27].
The aim of this study was not to validate the new CLAD
terminology [27], but to investigate any mechanistic differ-
ences between these clinical subphenotypes, which may
help us direct future basic and clinical research toward a
personalized treatment to further improve outcome after
LTx. The mechanistic elements being evaluated are airway
inflammation, inflammatory cytokine concentrations, IL-
1a alarmin concentrations, and epithelial cell viability.
Material and methods
Patients
Since October 2001, all lung transplant recipients at the
Leuven University Hospital have been enrolled in a routine
prospective bronchoscopy study. Physical and radiological
examination, systemic C-reactive protein (CRP), lung func-
tion, and bronchoscopy with bronchoalveolar lavage (BAL)
collection are performed at fixed time points after LTx or
in case of suspected complication. Bronchoalveolar lavage
samples were obtained from lung transplant recipients
from the Leuven Lung Transplant programme with hospi-
tal ethical committee approval (s51577), and all partici-
pants provided written informed consent. Bronchoalveolar
lavage procedure was performed as previously reported
[24]. Briefly for BAL, two aliquots of sterile saline (50 ml)
were instilled in the right middle lobe or lingula. The
returned fractions were pooled and processed for cell
counting and supernatant collection for protein measure-
ment and BEC stimulation. To be included in the study,
the patients needed a bronchoscopy and BAL collection at
the time of diagnosis of BOS, RAS, ARAD/LB, or PAN
without interfering factors such as infection, post-trans-
plant lymphoproliferative disorder (PTLD), and anasto-
motic complications. RAS (n = 9) was defined as a
combination of a persistent parenchymal infiltrates on
CAT scan together with a persistent TLC decline of more
than 10% or a decline in FEV1 of more than 20% and a
simultaneous decline in forced vital capacity (FVC), so that
the FEV1/FVC ratio was 0.7 or more, compatible with a
restrictive pulmonary function defect as previously
reported [26,29]. BOS patients (n = 13) were defined by a
persistent decline in FEV1 of more than 20%, without any
restrictive pattern of pulmonary function defect and with-
out another identifiable cause or confounding factor being
present. ARAD/LB patients (n = 10) histologically demon-
strated lymphocytic inflammation around the airways (B
grade acute rejection) without inflammation around the
blood vessels (A grade acute rejection) and were not on azi-
thromycin treatment for at least 3 months. PAN patients
(n = 10) were diagnosed with prior B grade rejection and
therefore were actively treated with azithromycin for at
least 2 months. In this patient group, azithromycin treat-
ment was started because of a previous episode of high BAL
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neutrophilia or re-transplantation (routine immunosup-
pression for re-transplant patients in our center includes
azithromycin treatment at discharge from the hospital). No
other interfering factors such as infection, post-transplant
lymphoproliferative disorder (PTLD), and anastomotic
complications were present. A control group was selected
and matched according to the mean sample time of the
whole rejection group. Additionally, as controls for BOS
and RAS, samples obtained from these two groups of
patients prior to diagnosis (pre-BOS and pre-RAS, respec-
tively) were also included in the study. A proposed pheno-
typic dichotomy of chronic lung allograft dysfunction is
presented in Fig. 1. Patient characteristics are shown in
Table 1. Primary bronchial epithelial cells (PBEC) were
obtained from a stable lung transplant recipient undergoing
surveillance bronchoscopy at the Freeman Hospital, New-
castle. (The study was approved by the regional ethics com-
mittee, and the patient provided written informed consent
to participate Ref. 2001/179.) IL-1a, IL-1b, IL-6, IL-8, and
TNF-a proteins were measured in undiluted BAL using
MSD electrochemiluminescence assay (MesoScale Discov-
ery, Gaithersburg, US) according to the manufacturer’s
instructions. Protein limits of quantification were 0.63 pg/
ml (IL-1a), 0.65 pg/ml (IL-1b), 0.64 pg/ml (IL-6), 3.33 pg/
ml (IL-8), and 0.66 pg/ml (TNF-a).
Epithelial cell culture and cell viability assay
Bronchoalveolar lavage samples used to stimulate PBEC
were centrifuged, and only the supernatants are used in the
BEC stimulation. Human PBEC were obtained by
bronchial brushings from an anonymous stable post-trans-
plant patient and cultured on 0.5% PureCol-coated dishes
in SABM (Lonza) medium. PBEC viability was performed
using XTT-based toxicity assay (Abcam) according to the
manufacturer’s instructions. Briefly, PBEC were seeded at
2 9 105 cells/ml in the final volume of 100 ll/well in a 96-
well culture plate. After 24 h, medium was replaced with
1:1 BAL supernatant/SABM. Following 24-h incubation at
37°C, 10 ll of XTT reagent was added to each well. After
1 h, OD corresponding to the relative cell metabolic activ-
ity was quantified using a multiwell plate reader. Relative
cell viability presented as optical density (OD) corresponds
to the formation of formazan dye by dehydrogenase
enzymes in metabolically active cells. All measurements
were taken at the wavelength of 450 nm and normalized to
blank (medium without cells with 10 ll XTT).
Statistical analysis
Results are expressed as mean  SEM. Kruskal–Wallis test,
Mann–Whitney U test, Spearman’s rank test, and paired
Student’s t-test were used where appropriate by Prism 4.1
software (San Diego, CA, USA).
Results
Patient characteristics
No significant differences were found between the patient
groups regarding gender, type of transplantation, blood
type, duration of cold ischemia, CMV match/mismatch,
immunosuppressive treatment, CRP, or post-LTx time of
Figure 1 Proposed dichotomy of chronic allograft dysfunction.
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BAL collection. A significant difference in age (P = 0.01)
was present with PAN patients being younger than control
patients [33 (22–57) vs. 57 (55–62) years, P < 0.05]. A sig-
nificant difference was found in underlying disease
(P < 0.0001). The Fisher exact test revealed that among
RAS patients, significantly less emphysema and CF were
present. Additionally, in classical BOS, significantly less OB
and other diseases were present. The PAN group included
more OB and the control group less interstitial lung disease
(Table 1).
Table 1. Patient characteristics.
Control LB/ARAD PAN
BOS RAS
P-value
Pre Diagnosis Pre Diagnosis
n = 13 n = 10 n = 10 n = 11 n = 13 n = 9
Median age
at Tx, years
57 (55–62) 55 (44–60) 33 (22–57) 51 (29–57) 42 (31–54) 0.010
Sex
Male 7 3 3 7 4 NS
Female 6 7 7 6 5
Pre-LTx diagnosis
Emphysema 9 7 3 4 1 <0.0001
Pulm. hypertension 2 0 1 0 2
Cystic fibrosis 1 2 2 4 0
Interstitial lung
disease
0 1 0 4 3
OB 0 0 2 1 0
Others 1 0 2 0 3
Type of LTx
Single 2 3 0 1 1 NS
Double 11 7 10 12 7
Heart–lung 0 0 0 0 1
Blood type
O 8 5 7 7 7 NS
A 3 3 3 3 1
B 2 2 0 3 1
Mean cold ischemia
Minutes 310 (259–329) 293 (217–356) 342 (325–385) 317 (298–418) 331 (281–341) NS
CMV match
Yes 8 6 3 8 3 NS
No 3 3 5 4 4
Unknown 2 1 2 1 2
Immunosuppressives
Steroids 13 10 9 11 12 8 7 NS
FK/cyclosporin 12/2 9/1 10/1 10/2 12/1 9/0 8/0 NS
AZA/MMF 4/2 6/2 2/2 7/1 7/2 5/2 5/1 NS
Azithromycin 1 0 10 1 1 1 0 NS
FEV1 (% pred) 102 (80–108) 60 (51–81) 52 (41–73) 81 (69–89) 65 (57–73) 68 (62–78) 58 (47–64) /
Time of BAL
Days post-Tx 731 (727–746) 584 (72–1743) 824 (351–2617) 379 (90–544) 1045 (335–2302) 735 (371–872) 916 (719–1455) NS
BAL return Ml 44 (38–51) 40 (36–42) 34 (28–37) 48 (42–54) 50 (39–53) 37 (31–41) 37 (30–55) 0.0082
Results are expressed as median (IQR). LB/ARAD, lymphocytic bronchiolitis/azithromycin reversible allograft dysfunction; PAN, persistent airway neutr-
ophilic despite azithromycin; BOS, classical bronchiolitis obliterans syndrome; RAS, restrictive allograft dysfunction; LTx, lung transplantation; CMV,
cytomegalovirus; PH, pulmonary hypertension; OB, obliterative bronchiolitis, FK, tacrolimus; AZA, azathioprine; MMF, mycophenolate mofetil. One-
way ANOVA and Fisher’s exact test are used; P < 0.05 is considered significant and significant values are shown in bold.
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Systemic CRP and BAL cellularity
Kruskal–Wallis ANOVA showed significant differences for
systemic CRP (P = 0.0075), number of BAL leukocytes
(P = 0.0001), percentage of BAL macrophages
(P < 0.0001), percentage of BAL neutrophils (P < 0.0001),
and percentage of BAL eosinophils (P = 0.028) as shown in
Fig. 2(a–e). No difference was observed for the percentage
of BAL lymphocytes (P = 0.49).
Leukocytes were increased in LB/ARAD (335 9 103
(79–1925 9 103) cells/ml; P = 0.0005), PAN (377 9 103
(26–37470 9 103) cells/ml; P = 0.0048), and BOS
(94 9 103 (80–306 9 103) cells/ml; P = 0.021) compared
with the control (51 9 103 (5–239 9 103) cells/ml). Leu-
kocytes were also increased in pre-BOS (88 9 103 (51–
544 9 103) cells/ml; P = 0.022) versus control, but not
versus BOS (0.3789) as assessed by paired Student’s t-test.
BAL neutrophilia (%) was increased in the LB/ARAD
[62.1% (11.8–92.8%); P < 0.0001], PAN [64% (9.4–
96.4%); P < 0.0001], BOS [2% (0.4–50.4%); P = 0.0051],
and RAS group [5% (0.4–82.2%); P = 0.0019] compared
with the control group [0.4% (0–4.5%)]. Neutrophilia of
both pre-BOS and pre-RAS groups was not different com-
pared with the control group. Eosinophil percentage was
only increased in RAS [0.6% (0–5%); P = 0.011] com-
pared with the control [0% (0–0.4%)]. Serum CRP was
higher in PAN [11.45 mg/l (1.2–41.9 mg/l); P = 0.0048]
and RAS [7.25 mg/l (1.5–52.1 mg/l); P = 0.0091] groups
compared with the control group [1 mg/ml (1–32.8 mg/
ml)] (Fig. 2).
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Figure 2 Systemic C-reactive protein and BAL cellular patterns within rejection phenotypes. The levels of systemic C-reactive protein (CRP) in blood
were measured by ELISA. (a), The number of white blood cells (WBC) (b), and the percentage of macrophages (c), neutrophils (d) and eosinophils (e)
in BAL of lung transplant recipients was measured by differential cell count. The different stars refer to the level of statistical significance (*P < 0.05,
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Protein profiles of cytokines in BAL
Kruskal–Wallis ANOVA showed significant differences in
BAL for IL-1a (P = 0.0002), IL-1b (P = 0.0001), IL-6
(P = 0.0006), IL-8 (P < 0.0001), and TNF-a (P < 0.0005)
(Fig. 3a–e). The IL-1a alarmin was significantly higher in
LB/ARAD [3.54 pg/ml (0.23–19.83 pg/ml); P = 0.033] and
PAN [5.03 pg/ml (0.99–72.6 pg/ml); P = 0.0011] versus
control [0.41 pg/ml (0.06–16.38 pg/ml)]. In pre-BOS
(P = 0.98), BOS (P = 0.20), pre-RAS (P = 0.79), and RAS
(P = 0.26), IL-1a was not different from the control;
however, it was higher in BOS compared with pre-BOS
(P = 0.015).
IL-1b levels were higher in LB/ARAD [23.11 pg/ml
(0.53–269.11 pg/ml); P = 0.03] and PAN [63.11 pg/ml
(11.21–1180.65 pg/ml); P < 0.0001] compared with the
control [1.23 pg/ml (0.39–30.88 pg/ml)]. IL-1b was not
different comparing the pre-BOS (P = 0.91), BOS
(P = 0.22), pre-RAS (P = 0.48), and RAS (P = 0.26) group
with the control group. IL-6 was increased in PAN
[18.88 pg/ml (0–18.71 pg/ml); P = 0.0007] and RAS
[6.820 pg/ml (0–371.1 pg/ml); P = 0.016] versus the con-
trol [1.14 pg/ml (0–8.4 pg/ml)]. IL-8 was increased in LB/
ARAD [280.5 pg/ml (10.12–26887.19 pg/ml); P = 0.016],
PAN [1073 pg/ml (325.22–22536.34 pg/ml); P < 0.0001],
and BOS [47.84 pg/ml (9.21–499.1 pg/ml); P = 0.047]
compared with control [11.95 pg/ml (3.33–337.31 pg/ml)].
TNF-a was only increased in PAN [24.13 pg/ml (9.89–
159.35 pg/ml); P = 0.0002] compared with the control
[1.78 pg/ml (0.46–22.11 pg/ml)] (Fig. 3).
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Figure 3 Cytokine and alarmin concentrations in BAL of lung transplant patients with different rejection phenotypes. IL-1a (a), IL-1b (b), IL-6 (c), IL-8
(d), and TNF-a (e) were measured in BAL using MSD assay. The different stars refer to the level of statistical significance (*P < 0.05, **P < 0.01,
***P < 0.001).
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Interaction of BAL with primary human bronchial
epithelial cells
To investigate the interactions of BAL with primary
human bronchial epithelial cells, PBEC were treated for
24 h with 1:1 BAL/media, after which cell viability was
assessed using XTT toxicity assay. BAL samples were cen-
trifuged, and only the supernatants were used in the PBEC
stimulation. Epithelial cell viability was significantly differ-
ent across the groups by Kruskal–Wallis ANOVA
(P = 0.034). The viability index of epithelial cells exposed
to BAL was significantly lower in PAN [0.318 (0.162–
0.457); P = 0.0094] compared with the control [0.416
(0.333–0.470)]. The viability index did not change for LB/
ARAD (P = 0.64), pre-BOS (P = 0.52), BOS (P = 0.11),
pre-RAS (P = 0.20), and RAS (P = 0.16) versus the con-
trol. The cell viability data are also presented as percentage
change in OD compared with untreated controls (cell
incubated in 1:1 media/PBS) (Fig. S1).
Additionally, a spearman correlation between PBEC via-
bility and concentrations of IL-1a, IL-1b, IL-6, IL-8, and
TNF-a was performed (Fig. 4b–f) in all groups together.
The analysis revealed an inverse correlation between all the
measured cytokines and PBEC viability (IL-1a, r = 0.24,
P = 0.042; IL-8, r = 0.36, P = 0.0017; IL-6, r = 0.24,
P = 0.045; IL-1b, r = 0.24, P = 0.045; and TNF-a,
r = 0.24, P = 0.039). Previous studies revealed that epi-
thelial damage is associated with release of alarmins includ-
ing IL-1a [21]. Therefore, we assessed the possible
relationship between levels of the epithelial alarmin IL-1a
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and proinflammatory BAL cytokines. The analysis revealed
a positive correlation between IL-1a and the measured
cytokines (IL-8, r = 0.73, P < 0.0001; IL-6, r = 0.61,
P < 0.0001; IL-1b, r = 0.72, P < 0.0001; and TNF-a,
r = 0.56, P < 0.0001) (Fig. 5).
Discussion
Phenotyping acute and chronic rejection after lung trans-
plantation has recently shown an important difference
between A grade and B grade (or LB) acute rejection and
between the distinct phenotypes of BOS, ARAD, and RAS
[25–27]. Lymphocytic bronchiolitis has been associated
with chronic lung allograft rejection for more than 15 years
[30]. After the initial observation that airway neutrophilia
predicts azithromycin responsiveness [25], we identified
lung transplant recipients with LB and persistently
increased airway neutrophilia, despite receiving azithromy-
cin therapy and termed this new phenotype as persistent
airway neutrophilia (PAN). Within BOS and RAS, we did
not observe changes in alarmins or cytokines. Both had an
increased BAL neutrophilia, and plasma CRP was also
increased in RAS. Importantly, RAS also demonstrated an
increased airway eosinophilia, which corroborates recent
findings by our group [28]. On the other hand, in the LB/
ARAD and especially in PAN, upregulation of proinflam-
matory cytokines was present.
Recently, Verleden et al. [28] demonstrated that
azithromycin treatment results in the reduction in IL-17-
positive cells in the lung biopsies of lung transplant
recipients with lymphocytic bronchiolitis/ARAD and not
in PAN. Activation of IL-17 T cells and stimulation of IL-
17 expression in neutrophils may be triggered by some
intracellular bacteria [31] and viruses [32], which may be
difficult to detect using standard microbiological methods.
On the other hand, the presence of IL-17 T cells was not
associated with infection in the aforementioned study.
Previous and our recent observations suggest that chronic
inflammatory lung diseases are associated with damage
and disruption of the integrity of the respiratory epithe-
lium and a release of epithelial alarmins including IL-1a.
Chronic inflammation is also a hallmark of BOS; however,
the levels of alarmins, proinflammatory cytokines, and
immune cells in BALs of patients with different rejection
phenotypes have not been investigated before. Therefore,
the objective of this study was to assess IL-1a, proinflam-
matory cytokines, and immune cells in BALs of lung
transplant recipients diagnosed with LB/ARAD, PAN,
BOS, and RAS and to investigate the interactions between
BAL from these different phenotypes and primary human
bronchial cells.
Our study revealed that PAN is characterized by elevated
levels of IL-1a, IL-1b, IL-8, IL-6, and TNF-a, of which the
latter two seem only to be elevated in PAN. Moreover,
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Figure 5 Correlation between a marker of epithelial injury, IL-1a, and proinflammatory cytokines in BAL of lung transplant patients. Correlation
between IL-1a and IL-8 (a), IL-6 (b), IL-1b (c), and TNF-a (d) concentrations in BAL was assessed using Spearman’s rank correlation coefficient. The
analysis was performed in all groups together. The different stars refer to the level of statistical significance (*P < 0.05, **P < 0.01, ***P < 0.001).
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PAN was the only phenotype in which the lavage fluid
(containing airway surface liquid from airways as well as
the alveolar space) caused decreased epithelial cell viability.
Both LB/ARAD and PAN are associated with increased
numbers of BAL neutrophils. The main neutrophil chemo-
attractant, IL-8, was also significantly increased in BAL of
these patients.
IL-8 is one of the most potent neutrophil chemoattrac-
tants, whose expression may be triggered by a variety of
factors including IL-1a [33], TNF-a [34] and IL-1b [35].
Additionally, previous reports demonstrated that there is a
link between epithelial damage, inflammation, and neutro-
philia [36]. These reports are in agreement with our observa-
tions that there is an inverse correlation between PBEC
viability and concentrations of proinflammatory cytokines
in BALs. Identification of BAL-originated factors that trigger
the epithelial damage would shed more light on the underly-
ing cause of chronic inflammation and degeneration of the
respiratory epithelium in patients with high neutrophilia
who do not respond to azithromycin treatment.
Both IL-1a and IL-1b were significantly increased in
PAN and LB/ARAD. The potential sources of IL-1a in PAN
may be damaged epithelial cells. IL-1b and TNF-a may also
originate from activated macrophages, and IL-1a may be
released by macrophages and neutrophils undergoing
apoptosis. Interestingly, TNF-a, which also may trigger IL-
8 expression and contribute to neutrophil influx, was sig-
nificantly increased only in PAN but not in LB/ARAD, sug-
gesting that the pathogenesis of these two CLAD
phenotypes may have different backgrounds; however, fur-
ther studies are required to identify the mechanistic differ-
ences between these two phenotypes. Additionally, IL-8-
mediated neutrophilia in LB/ARAD may be triggered by
IL-17 secreted by Th17 cells whose presence was detected in
lung sections from CLAD patients responsive to azithromy-
cin [28].
Previous studies demonstrated that IL-17 expressing
cells are present in the airways of LB/ARAD patients and
that IL-17 induces expression of a neutrophil chemokine
IL-8. It was also confirmed that interactions between neu-
trophils and T cells may modulate T-cell responses. The-
wissen et al. [37] have shown that the presence of PMN
in the co-culture dose-dependently increased the fraction
of IFNc and IL-17 producing T cells and decreased the
percentage of IL-10 producing CD4(+) T cells, suggesting
that persistent neutrophilia may polarize T cells into Th1/
Th17 phenotype. Additionally, IL-1b that may be released
by activated neutrophils may trigger expression of IL-17
in T cells and is required for Th17 cell differentiation and
maturation. Moreover, IFNc produced by Th1 and Th17
cells is required for the activation of M1 macrophages,
which are a source of the neutrophil chemoattractant, IL-
8 [37].
Interestingly, our study demonstrated that proinflamma-
tory cytokines did not change in BOS and RAS despite the
presence of a neutrophilia.
In addition, the detected eosinophilia in RAS is a poten-
tial new concept to consider. Eosinophilia has been
reported in the past in chronic rejection [38], yet never
explored further. Classical BOS is becoming an increasingly
difficult phenotype to increase mechanistic understanding
of. Although more and more of the previously identified
risk factors can be linked with the other phenotypes,
ARAD (neutrophilia, IL-1b, IL-8, IL-6, and TNF-a, CRP)
and RAS (eosinophilia, CRP), protein profiles observed in
this and previous reports [27] do not show significant
changes.
Considering that chronic lung rejection or CLAD may
evolve to RAS or BOS, which are characterized by distinct
histological features, it may be that genetic or epigenetic
features determine the fate of the allograft after transplanta-
tion; however, further studies are required to test this
hypothesis.
One of the limitations of the study was a small
number of samples in each group. The groups were
not significantly different except for age, which is an
example of this small sample size effect. This manu-
script does provide provocative data that should be val-
idated in a larger multicenter study as it clearly
demonstrates that different pathways are involved in
LB/ARAD, PAN, BOS, and RAS, which may allow the
development of targeted therapies in the future.
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Figure S1. PBEC were cultured in 1:1 BAL/SABM media
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(cell incubated in 1:1 media/PBS).
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